Trending

Galapagos

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

Galapagos and MorphoSys have announced that they are ending the clinical development programme for their drug MOR106 in

X

Novartis’ $100m bet on eczema drug fails as MOR106 development ends

https://pharmaphorum.com/news/novartis-100m-bet-on-eczema-drug-fails-as-mor106-development-ends/

Gilead says arthritis drug filgotinib fails in follow-up use trials

Gilead says arthritis drug filgotinib fails in follow-up use trials

As Gilead and Galapagos prepare their JAK inhibitor filgotinib for a US filing in rheumatoid arthritis, the drug

X

Gilead says arthritis drug filgotinib fails in follow-up use trials

https://pharmaphorum.com/news/gilead-says-arthritis-drug-filgotinib-fails-in-follow-up-use-trials/

Gilead invests $5.1bn in Belgian biotech Galapagos

Gilead invests $5.1bn in Belgian biotech Galapagos

Belgian biotech Galapagos has signed a shiny new deal with Gilead to develop inflammatory disease and rheumatoid arthritis

X

Gilead invests $5.1bn in Belgian biotech Galapagos

https://pharmaphorum.com/news/gilead-invests-5-1bn-in-belgian-biotech-galapagos/

Galapagos shares surge on RA drug trial results

Galapagos shares surge on RA drug trial results

Shares in the Belgian biotech Galapagos have surged after a late stage trial of filgotinib, a rheumatoid arthritis drug

X

Galapagos shares surge on RA drug trial results

https://pharmaphorum.com/news/galapagos-shares-surge-drug-trial-results/

Novartis pays up to $1 billion for potential eczema drug

Novartis pays up to $1 billion for potential eczema drug

Swiss pharma Novartis is to pay up to $1 billion to Galapagos and MorphoSys for exclusive rights to

X

Novartis pays up to $1 billion for potential eczema drug

https://pharmaphorum.com/news/novartis-increases-its-immunology-footprint-with-1-billion-deal/

Gilead could make a move for Galapagos within weeks

Gilead could make a move for Galapagos within weeks

The share price of Belgium-Dutch biotech Galapagos is rising thanks to renewed speculation that Gilead may be poised

X

Gilead could make a move for Galapagos within weeks

https://pharmaphorum.com/news/gilead-make-move-galapagos-within-weeks/

Galapagos and FibroGen drugs offer hope in IPF

Galapagos and FibroGen drugs offer hope in IPF

Drugs improve on existing medicines from Boehringer and Roche.

X

Galapagos and FibroGen drugs offer hope in IPF

https://pharmaphorum.com/news/galapagos-fibrogen-ipf/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com